866-997-4948(US-Canada Toll Free)

Radiation Toxicity - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : May 2017

Category :

Diseases & Conditions

No. of Pages : 202 Pages

Radiation Toxicity - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Radiation Toxicity - Pipeline Review, H1 2017, provides an overview of the Radiation Toxicity (Toxicology) pipeline landscape.

Radiation Toxicity (also known as radiation sickness) is an acute illness caused by irradiation of the entire body by a high dose of penetrating radiation in a very short period of time (usually a matter of minutes). The major cause of this syndrome is depletion of immature parenchymal stem cells in specific tissues. Symptoms include bleeding from the nose, mouth, gums, and rectum, bloody stool, bruising, confusion, dehydration, diarrhea, fainting and fatigue

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Radiation Toxicity - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Radiation Toxicity (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Radiation Toxicity (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 5, 7, 46, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

Radiation Toxicity (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Radiation Toxicity (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Radiation Toxicity (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Radiation Toxicity (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Radiation Toxicity (Toxicology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Radiation Toxicity (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Radiation Toxicity (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Overview 9
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Development 10
Pipeline Overview 10
Pipeline by Companies 11
Pipeline by Universities/Institutes 15
Products under Development by Companies 16
Products under Development by Universities/Institutes 20
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Assessment 21
Assessment by Target 21
Assessment by Mechanism of Action 24
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Companies Involved in Therapeutics Development 31
Aeolus Pharmaceuticals Inc 31
Angion Biomedica Corp 31
Atox Bio Ltd 32
BCN Biosciences LLC 32
Bolder Biotechnology Inc 33
Cellerant Therapeutics Inc 33
Cellphire Inc 34
Chrysalis BioTherapeutics Inc 34
Cleveland BioLabs Inc 35
Daiichi Sankyo Company Ltd 35
FirstString Research Inc 36
Foresee Pharmaceuticals LLC 36
Galera Therapeutics Inc 37
Genzyme Corp 37
GNI Group Ltd 38
Humanetics Corp 38
Insys Therapeutics Inc 39
Meabco A/S 39
Neumedicines Inc 40
Nohla Therapeutics Inc 40
Onconova Therapeutics Inc 41
Original BioMedicals Co Ltd 41
PharmaIN Corp 42
Pluristem Therapeutics Inc 42
RDD Pharma Ltd 43
Reata Pharmaceuticals Inc 43
RedHill Biopharma Ltd 44
RxBio Inc 44
Shuttle Pharmaceuticals LLC 45
SK Chemicals Co Ltd 45
Soligenix Inc 46
Synedgen Inc 46
Tonix Pharmaceuticals Holding Corp 47
TSRL Inc 47
viDA Therapeutics Inc 48
Windtree Therapeutics Inc 48
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Drug Profiles 49
(levocetirizine dihydrochloride + montelukast sodium) - Drug Profile 49
A-02 - Drug Profile 50
AB-103 - Drug Profile 51
ABC-294640 - Drug Profile 54
AEOL-10171 - Drug Profile 61
Aerosurf - Drug Profile 62
amifostine - Drug Profile 67
amifostine - Drug Profile 68
AVMOC-001 - Drug Profile 69
BB-3 - Drug Profile 70
BBT-007 - Drug Profile 74
BBT-015 - Drug Profile 75
BBT-018 - Drug Profile 76
BBT-059 - Drug Profile 77
BCN-057 - Drug Profile 78
BIO-300 - Drug Profile 79
BMX-001 - Drug Profile 82
BPC-2 - Drug Profile 84
C-2E2 - Drug Profile 85
C-2E5 - Drug Profile 86
Cell Therapy for Acute Radiation Syndrome - Drug Profile 87
cerium oxide - Drug Profile 88
CLT-009 - Drug Profile 89
Des-Asp Angiotensin 1 - Drug Profile 90
DG-3 - Drug Profile 91
entolimod - Drug Profile 92
EWA-001 - Drug Profile 99
Fibrinoplate-S - Drug Profile 100
FP-045 - Drug Profile 101
Granexin - Drug Profile 102
HSJ-0017 - Drug Profile 104
JP4-039 - Drug Profile 105
LGM-2605 - Drug Profile 107
m-2A2 - Drug Profile 108
MDY-1001 - Drug Profile 109
molgramostim - Drug Profile 110
NAS-911 - Drug Profile 111
NMIL-121 - Drug Profile 113
omaveloxolone - Drug Profile 117
ondansetron hydrochloride - Drug Profile 120
ondansetron hydrochloride CR - Drug Profile 121
Peptide to Agonize GHSR for Acute Ischemic Stroke, Acute Radiation Syndrome and Sepsis - Drug Profile 128
pirfenidone - Drug Profile 129
PLXR-18 - Drug Profile 131
Preimplantation Factor - Drug Profile 138
QR-205 - Drug Profile 139
RDD-2007 - Drug Profile 140
recilisib sodium - Drug Profile 141
Recombinant Protein C for Sepsis, Stroke and Radiation Toxicity - Drug Profile 143
Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile 144
Recombinant Protein to Activate FGF-4 for Radiation Injury - Drug Profile 145
Recombinant Protein to Activate FGF-7 for Radiation Injury - Drug Profile 146
RP-239X - Drug Profile 147
RS-9 - Drug Profile 148
rusalatide acetate - Drug Profile 149
Rx-100 - Drug Profile 153
sargramostim - Drug Profile 155
SGX-201 - Drug Profile 158
SGX-202 - Drug Profile 159
SKI-2162 - Drug Profile 162
Small Molecule for Prostate Cancer, Asthma and Radiation Injury - Drug Profile 163
Small Molecule for Radiation Toxicity - Drug Profile 164
Small Molecule for Radiation Toxicity 1 - Drug Profile 165
Small Molecule to Antagonize Adenosine A2A Receptor for Radiation Dermatitis - Drug Profile 166
Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology - Drug Profile 167
SP-3001 - Drug Profile 168
ST-266 - Drug Profile 169
ST-7 - Drug Profile 172
SY-513 - Drug Profile 173
SYGN-305 - Drug Profile 174
SYGN-399 - Drug Profile 175
Thrombosomes - Drug Profile 176
TNX-701 - Drug Profile 177
TPO-7630 - Drug Profile 178
TPO-7640 - Drug Profile 180
VEDA-1209 - Drug Profile 181
VTI-1000 Series - Drug Profile 182
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects 183
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products 186
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Product Development Milestones 187
Featured News & Press Releases 187
Appendix 196
Methodology 196
Coverage 196
Secondary Research 196
Primary Research 196
Expert Panel Validation 196
Contact Us 196
Disclaimer 197

List of Tables
Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Aeolus Pharmaceuticals Inc, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Angion Biomedica Corp, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Atox Bio Ltd, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by BCN Biosciences LLC, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Bolder Biotechnology Inc, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cellerant Therapeutics Inc, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cellphire Inc, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Chrysalis BioTherapeutics Inc, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cleveland BioLabs Inc, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by FirstString Research Inc, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Foresee Pharmaceuticals LLC, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Galera Therapeutics Inc, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Genzyme Corp, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by GNI Group Ltd, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Humanetics Corp, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Insys Therapeutics Inc, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Meabco A/S, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Neumedicines Inc, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Nohla Therapeutics Inc, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Onconova Therapeutics Inc, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Original BioMedicals Co Ltd, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by PharmaIN Corp, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Pluristem Therapeutics Inc, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RDD Pharma Ltd, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Reata Pharmaceuticals Inc, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RedHill Biopharma Ltd, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RxBio Inc, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Shuttle Pharmaceuticals LLC, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by SK Chemicals Co Ltd, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Soligenix Inc, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Synedgen Inc, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by TSRL Inc, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by viDA Therapeutics Inc, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Windtree Therapeutics Inc, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H1 2017 (Contd..1), H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H1 2017 (Contd..2), H1 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Top 10 Routes of Administration, H1 2017
Number of Products by Stage and Top 10 Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *